A REVIEW OF AN CURRENT AND FUTURE THERAPEUTIC PERSPECTIVE IN HEART FAILURE

Sopan Kondiba Ghuge[1], Shaikh.S.M.J[2]
Nandkumar Shinde College Of Pharmacy, Vaijapur. Dr. Babasaheb Ambedkar Technological University, Lonare, Maharashtra, India

ABSTRACT

The prevalence of heart failure is primarily flat or declining for a presumably reflecting better operation of cardiovascular conditions, but that of heart failure with saved ejection bit(HFpEF) is presumably adding for the lack of an established effective treatment. Also, there's no specific pharmacological treatment for cases with heart failure with mildly reduced ejection bit(HFmrEF) since no substantial prospective randomized clinical trial has been performed simply in similar population. According to the recent 2021 European Society of Cardiology(ESC) guidelines, the trio composed of an Angiotensin

Converting Enzyme asset or Angiotensin Receptor- Neprilysin Asset(ARNI), a beta-blocker, and a Mineralcorticoid Receptor Antagonist is the foundation remedy for all cases with heart failure with reduced ejection bit(HFrEF) but a substantial gap exists for cases with HFpEF/ HFmrEF. Despite the important part of the Renin- Angiotensin- Aldosterone System(RAAS) in heart failure pathophysiology, RAAS blockers were set up ineffective for HFpEF cases. Indeed, indeed the new medicine class of ARNI was set up effective only in HFrEF cases. In this regard, a remedial volition may be represented by medicine stimulating thenon-classic RAAS(ACE2 and A1 – 7) as well as other arising medicine classes(similar as SGLT2 impediments). Reflecting on this global health burden and the gap in treatments among heart failure phenotypes, we epitomize the leading players of heart failure pathophysiology, the available pharmacological treatments for each heart failure phenotype, and that in unborn development.

Keyword: *Treatment, Heart failure with preserved ejection fraction, Chronic heart failure, Therapeutic perspective, Renin-angiotensin- aldosterone system.*

1.TITLE

Cardiovascular conditions (CVDs) are a group of diseases of the heart and blood vessels that represents the leading cause of global deaths. As estimated by the World Health Organization,17.9 million people failed for CVDs in 2019, representing 32% of all global deaths [1]. CVDs include a significant number of conditions similar as coronary heart complaint, cerebrovascular complaint, supplemental arterial complaint, rheumatic heart complaint, heart failure, and natural heart complaint. Among them, numerous sweats have been made to treat better and manage heart failure. According to the recent 2021 European Society of Cardiology(ESC) guidelines[2], heart failure is a clinical pattern characterized by a structural/ functional abnormality of the heart that results in elevated intracranial pressures and shy cardiac affair at rest or during exercise. Abecedarian for the heart failure opinion and treatment is the identification of the underpinning cardiac dysfunction. Utmost generally, heart failure can be caused by a systolic or diastolic dysfunction, or both. Still, in some cases, the presence of pathology of the faucets, pericardium, and endocardium, or heart meter abnormalities can also contribute to the onset of heart failure. Moment, heart failure is classified into three phenotypes grounded on the dimension of left ventricular

ejection bit(LVEF), which can be reduced, with a value of ≤ 40(heart failure with reduced ejection bit, HFrEF); mildly reduced, with a value ranging between 41 and 49(heart failure with mildly reduced ejection bit, HFmrEF); saved, with a value of ≥ 50(heart failure with saved ejection bit, HFpEF)[2]. Recent data have suggested that the prevalence of heart failure is primarily flat or declining for a presumably reflecting better operation of CVDs [2],[3], but that of HFpEF is presumably adding for the lack of an established effective treatments for HFpEF[3]. This highlights an essential difference in treating different heart failure phenotypes and strengthening the exploration on HFmrEF and HFpEF. In fact, as a difference, numerous effective medicines are available, and numerous others are under disquisition showing satisfying results for the HFrEF[2]. Eventually, it should also be considered that over all the mortality and hospitalization for heart failure remains high [3].

2. NEUROHORMONAL SYSTEMS IN HEART FAILURE:

Neuro- hormonal systems, including the Sympathetic Nervous System (SNS), the Renin-Angiotensin- Aldosterone System (RAAS), and the Natriuretic Peptides(NPs) system, share in heart failure pathophysiology. These systems are actuated at the early phase to increase the myocardial contractility, the ventricular stuffing, and the supplemental vasoconstriction, which have the final thing of maintaining the perfusion of vital organs. Still, dragged activation of these systems is also responsible for heart failure progression and inimical prognostic. Indeed, SNS and RAAS can beget cardiac damage intermediates by an increase in the left ventricular after load and preload, an increase in heart rate, myocardial hypertrophy, fibrosis, and apoptosis [4]. Specifically, the hyperactivation of the SNS results in cardiac dysfunction [5], through the activation of β1 and β2 adrenergic receptors. These receptors are involved, with contrary mechanisms, in the pathophysiology of heart failure; there's substantiation that receptor β1 is involved in apoptotic signaling, while receptor β2 appears to stimulate both autophagy and antiapoptotic responses [6]. Also, the stimulation of the renal juxtaglomerular adrenergic receptor β1 contributes to the activation of the RAAS system, which determines cardiac redoing and apoptosis [7].

The main middleman of the RAAS system is the angiotensin II(AII) [8], AII promotes the development of arterial vasoconstriction, vascular redoing, hydrosaline retention, oxidative stress, myocardial fibrosis, and an increase in aldosterone tube situations [9],. These goods are substantially due to the commerce of AII on its AT1 receptor. rather, contrary goods are determined by its commerce on the AT2 receptor [10]. also, another angiotensin, Angiotensin III, which is formed by the action of aminopeptidase A(APA), also acts on AT1 and AT2 receptors [11]. The preclinical substantiation related to the implicit block of AIII conformation is dated back to the 90s [12], but it was also cited by more recent workshop [13]. remedial strategies inhibiting APA may be delved in the environment of heart failure as preclinical results demonstrated a forestalled of cardiac dysfunction, a normalization of brain APA hyperactivity, and an attenuation of cardiac hypertrophy and fibrosis with the APA asset firibastat [14]. While the adding knowledge of the part of AIII carries the translational eventuality, the issue whether the benefits from blocking APA are related to an increase of brain AIII situations is batted [15]and the origins and dynamics of the angiotensin in the central nervous system aren't fully clear. Considering that APA metabolizes also other substrates similar as neurokinin B, cholecystokinin- 8, and chromogenic A that could as well play a part in cardiovascular homeostasis, the molecular consequences of the firibastat can extend beyond AIII [16]. Lately, an indispensablenonACE-dependent pathway (non-classic RAAS) involving other peptide intercessors and enzymes has been linked. The central middleman is angiotensin 1 – 7 (A1–7), which conflation is shown in [17],[18],. Utmost substantiation shows that A1 – 7 could spark the G protein-coupled receptor MAS1 and promoteantiinflammatory,anti-fibrotic, andanti-thrombotic goods[11]. On the other hand, some data suggest that the salutary effect of A1 – 7 in counter regulating the AII- AT1 axis isn't directly attributable to the commerce with recombinant MAS12 [19]. The NPs system also plays a vital part in maintaining

cardiovascular homeostasis in cases with habitual heart failure [20]. It's an endocrine, autocrine and paracrine system composed of the atrial natriuretic peptide (ANP), the natriuretic peptide type B or" brain natriuretic peptide"(BNP), and the natriuretic peptide type C(CNP)[21]. NPs ply their natural exertion through the receptors NPR- A, NPR- B, and NPR- C. While NPR- A and NPR- B receptors are guanylate cyclase receptors, NPR- C receptors act as" concurrence receptors" and remove NPs from the systemic rotation [22]. Considering the positive goods determined by NPs, they presumably are a compensatory medium to evaluate the injurious RAAS- convinced impact [23].



3. PHARMACOLOGICAL TREATMENTS:

Pharmacotherapy is the foundation of the treatment of heart failure, and it can be divided grounded on the phenotype of heart failure. A schematic representation of the main mechanisms of action of medicines used delved for heart failure, and the characteristics of similar specifics are epitomized in Table 1.

3.1 Agents Used for Treatment for Heart Failure:

ACE Inhibitors:

work by adding vasodilation and dwindling workload of the heart in cases with CHF.

Diuretics:

promote the junking from the body of redundant water, mariners, venous, and accumulated metabolic products, similar as urea. See also Aldosterone Receptor Antagonist.

Glucosides and Congestive Heart Failure: a class of medicines that includes digoxin, digoxin and Urban. Similar agents increase the force of compression of the heart (i.e. a positive isotropic action) which underlies their use in some cases of heart failure (24).

Beta-Blockers:

(mild-to-moderate complaint) drop the inordinate exertion of the sympathetic nervous system which is characteristic of CHF. (mild-to moderate complaint) Selection of agents and

their combinations depend on original clinical state and on patient responsiveness to cosign remedy.

Therapeutic class	Drugs	Main mechanism of action	Main adverse events	Main Drug-drug interactions
ACE-inhibitors	Captopril Enalapril Lisinopril Ramipril Trandolapril	Inhibition of AII synthesis by blocking the ACE	Cough, hypotension, dyspnea, dizziness, headache, gastrointestinal symptoms	Trimethoprim/sulfamethoxazole, mTOR inhibitors, other RAAS-inhibitors, other antihypertensive drugs, NSAIDs, lithium
β-blockers	Bisoprolol Carvedilol Metoprolol Nebivolol	B adrenergic receptor antagonists	Bradycardia, hypo/hypertension, hypervolemia, gastrointestinal symptoms, edema, respiratory and urinary tract infections, hyperglycemia and asthma	Digoxin, cyclosporine, CYP2D6 and 2C9 inducers, amiodarone, fluoxetine, paroxetine, clonidine, diltiazem
MRAs	Eplerenone Spironolactone Potassium canrenoate	Aldosterone receptor antagonists	Hypokalaemia, hypercholesterolemia, insomnia, dizziness, syncope, headache, left ventricular failure, atrial fibrillation, hypotension, cough, gastrointestinal symptoms, cutaneous reactions, muscle spasms, renal damage	Potassium-sparing diuretics, ACE-inhibitors, lithium, ciclosporin, tacrolimus, NSAIDs, trimethoprim, α1-blockers, tricyclic antidepressants, neuroleptics, glucocorticoids
ARNI	Sacubitril/ valsartan	Neprilysin inhibitor (sacubitril) and angiotensin receptor blocker (valsartan)	Cough, dizziness, hyperkalaemia, hypoglycemic, swelling, kidney failure (renal failure), anemia, headache, gastrointestinal symptoms, fatigue	RAAS-inhibitors, potassium, NSAIDs, lithium, metformin, PDE5-inhibitors
Gliflozines	Dapagliflozin Empagliflozin	SGLT2-inhibitors	Urinary tract infections, dizziness, cutaneous reactions, dysuria and polyuria, increased creatinine, decreased weight	Diuretics, mefenamic acid, rifampicin
Positive inotropic agents	Omecamtiv mecarbil	Activation of cardiac myosin and increase in the rate of ATP	Dyspnea, ventricular extrasystoles, hypertension, photopsia, rhinitis	–

Table 1. Characteristics of main therapeutic classes/ investigated in patient with heart failure.

4. PHARMACOTHERAPY OF HRREF:

As reported in the 2021 ESC guidelines, the foundation of pharmacotherapy of HFrEF includes medicines suitable to modulate the RAAS, the SNS, or the natriuretic peptide system, similar as ACE impediments, angiotensin receptor-NEP asset (ARNI), beta-blockers, and mineralocorticoid receptor antagonists (MRAs). These medicines have all been demonstrated to reduce mortality and the threat of hospitalizations or symptoms [2]. ACE impediments (e.g., captopril, enalapril, lisinopril, ramipril, trandolapril) other than blocking the conversion of AI into AII, can grease the AI conversion into A1 – 7 that can further contribute to the cardiovascular benefit [25]. Still, there's no data on the difference in A1 – 7 situations attained by comparing other RAAS blockers. MRAs (eplerenone, potassium carbonate, and spironolactone) are aldosterone antagonists also honored to produce cardiovascular benefits in treating HFrEF when added to an ACE-asset a beta-blocker. Numerous new composites with anon-steroidal structure (similar as finerenone) are under disquisition to gain an MRA that exerts cardiovascular benefits without determining renal adverse events [11]. In this regard, the first results showed that finerenone was well permitted and convinced a 30 or lesser reduction in NT- proBNP situations in a analogous proportion of cases treated with eplerenone [26]. Eventually, a head- to- head clinical trial is ongoing comparing spironolactone and eplerenone in cases with HFrEF (ClinicalTrials.gov Identifier NCT03984591; Supplementary table 1). According to the agreement, β- blockers P (e.g., bisoprolol, carvedilol, metoprolol, nebivolol) can be started with ACE impediments as soon as the opinion of characteristic HFrEF is established [27]. Different types of β-blockers are presently approved for heart failure and original algorithm for choosing them grounded on the knowledge of cardiopulmonary pathophysiology have been developed [28]. Eventually, ARNI is a new medicine class that combines the angiotensin II receptor blocker (ARB) valsartan with the NEP asset sacubitril [29]. Sacubitril-losartan showed a lesser reduction of cardiac deaths and hospitalization for heart failure compared to the ACE asset enalapril. Other fresh benefits of sacubitril- losartan were an enhancement in symptoms and quality of life [30], reduction in the prevalence of diabetes taking insulin treatment [31], a reduction in the estimated glomerular filtration rate (eGFR) decline [32] and hyperkalaemia [33], and a reduction in need of circle diuretic [34]. Other clinical trials are ongoing on adult cases with HFrEF and pediatric cases with heart failure (table 1). The 2021 ESC guidelines on heart failure recommend the trio composed of an ACE asset or ARNI, a beta- blocker, and an MRA in cases with HFrEF unless these medicines are contraindicated or not permitted. These guidelines, as the former interpretation still recommend the use of an ARNI as a relief for the ACE asset in suitable cases who remain characteristic after the treatment with ACE asset, beta- blocker, and MRA, but they also add the possibility of choosing an ARNI as first- line remedy rather of an ACE asset. Eventually, using the ARB alone (candesartan, losartan) preserves a part in those cases who don't tolerate the ACE asset or the ARNI. A new class of medicines introduced for the treatment of HFrEF is represented by sodium- glucoseco-transporter 2(SGLT2) impediments (Gliflozines) similar as dapagliflozin and empagliflozin. These medicines were first approved for the treatment of type 2 diabetes mellitus and have lately entered marketing authorization for the treatment of HFrEF anyhow of diabetes grounded on the positive results of two clinical trials (DAPA-HF and EMPEROR- Reduced) [35],[36]. also, their benefit goods in terms of cardiovascular and each- beget mortality were shown in a meta- analysis of DAPA- HF (assessing dapagliflozin) and EMPEROR- Reduced (assessing empagliflozin) trials [37]. Several mechanisms have been supposed to determine these cardiovascular benefits, including pleiotropic goods on bibulous diuresis and natriuresis contributing to blood pressure-lowering without a compensatory increase of SNS, and dropped arterial stiffness vascular resistance, reduction of body weight and visceral obesity, dropped uric acid and oxidative stress, and reduction of inflammation [38].

5. PHARMACOTHERAPY OF HFMREF:

There's no specific pharmacological treatment for cases with HFmrEF since no substantial prospective randomized clinical trial has been performed simply in such a population. still, some data can be uprooted from a group analysis of trials conducted in cases with HFpEF, which don't have met their primary endpoints. nevertheless, clinical substantiation suggested that cases with EF in the 40 – 50 range may profit from remedy recommended for HFrEF. At this regard, the 2021 ESC guidelines on heart failure stated that" although no strong recommendations for this heart failure phenotypes can be made, some medicines similar as ACE impediments, ARB, MRA, beta-blockers, and ARNI can be considered to reduce the threat of death and heart failure hospitalization".

6. PHARMACOTHERAPY OF HFPEF:

Presently, there's a gap in the treatment of HFpEF, and utmost approved medicines for HFrEF are ineffective for HFpEF. This has suggested the presence of significant differences in the abecedarian pathophysiology and remedial targets of HFpEF compared to HFrEF. The HFpEF is a miscellaneous clinical pattern in which attend different comorbidities similar as rotundity, diabetes, hypertension, atrial fibrillation, order dysfunction, and metabolic pattern and systemic inflammation plays a major part [39]. nonetheless, it should be considered that the opinion of HFpEF is still grueling, although several individual criteria have been proposed over the times. In this regard, the 2021 ESC guideline recommends a simplified approach for diagnosing HFpEF, which considers the common major rudiments of opinion and emphasizes the most constantly used variables from clinicians similar as the left patio size, mitralE-wave haste, and septal e' haste. Clinical trials on perindopril (vim- CHF) [40], candesartan (CHARM- saved), irbesartan (I- PRESERVE) [41], spironolactone (TOPCAT) [42], digoxin (DIG- saved) [43], and sacubitril-losartan (eidolon- HF) failed to convincingly reduce morbidity and mortality in similar cases. In particular, the eidolon- HF trial, probing the innovative association sacubitril- valsartan, showed no difference in the primary end point (hospitalizations for heart failure and cardiovascular deaths) compared to valsartan alone (rate rate,0.87; 95 CI,0.75 –1.01; P = 0.06) [44].

Another study probing sacubitril – valsartan among cases with HFmEF or HFpEF is the PARALLAX clinical trial that showed a reduction in NT- proBNP but not an enhancement in 6-nanosecond walk distance when sacubitril/ valsartan was compared to personalized medical remedy [45]. Eventually, the PARAGLIDE- HF clinical trial is still ongoing to probe the effect of sacubitril – valsartan on changes in NT- proBNP, issues, and safety in cases with HFpEF (ClinicalTrials.gov Identifier NCT03988634). also, another remedial class for treating cases with HFpEF is that of MRAs (spironolactone and eplerenone). still, as stressed in a review, fresh data are necessary to define better the threat- benefit profile of MRAs in HFpEF cases [46]. presently, two phase 3 clinical trials are ongoing to probe the efficacity of spironolactone in cases with HFpEF/ HFmEF (clinical Trials.gov Identifier NCT02901184; Supplementary table 1), and one phase 3 clinical trial is studying thenon-steroidal MRA finerenone in cases with HFmEF/ HFpEF. Eventually, SGLT2 impediments are also being delved in HFpEF. Indeed, the results of the EMPEROR- saved clinical trial, probing empagliflozin compared to placebo in cases with class II- IV of heart failure and an ejection bit of further than 40, have been lately published on August 2021.

The EMPEROR- saved trial showed that the empagliflozin group had a lower threat of cardiovascular death or hospitalization for heart failure compared to the placebo group (hazard rate,0.79; 95CI,0.69 –0.90; P<0.001) and that this effect was harmonious in cases with or without diabetes. also, it was harmonious across prespecified ejection bit groups with a LVEF< 50 (hazard rate,0.71; 95CI,0.57 – 0.88) or ranged between 50 to< 60 (hazard

rate,0.80; 95CI,0.64 –0.99). The most constantly reported adverse responses with empagliflozin were uncomplicated genital and urinary tract infections and hypotension [47]. These results are the first showing a successful efficacity in cases with HFpEF and can make empagliflozin a new standard treatment for similar cases who don't have remedial options [48]. These findings are also supported by recent results of a pooled analysis of two randomized trials (EMPEROR- reduced and
EMPEROR- saved) presented at the ESC congress 2021. This analysis showed that empagliflozin reduced the threat of heart failure hospitalization to a analogous degree (about 30 threat reduction) in cases with HFrEF and HFpEF and that the magnitude of the effect on heart failure hospitalizations was analogous across a broad range of ejection fragments below 65 [49]. The enhancement of symptoms in HFpEF cases treated with SGLT2 impediments may be incompletely due to their metabolic pathways in ketogenic metabolism [50]. Interest in a mechanistic aspect led to identification of several molecular and cellular mechanisms by which SGLT2i contribute to the protection against heart failure and unforeseen death observed in clinical trials. Alongside other pleiotropic goods (systemic hemodynamic and metabolic goods), SGLT2i directly target cardiac cells including cardiomyocytes and endothelial cells interacting with SGLT1, NHE1 and Nav 1.5 [51]. Eventually, an ongoing phase 3 clinical trial (DELIVER) evaluates dapagliflozin compared to placebo in cardiovascular death and heart failure events in cases with HFpEF(ClinicalTrials.gov Identifier NCT03619213).

Also other clinical trials with SGLT2 impediments are ongoing (Supplementary table 1). Grounded on the current substantiation, the possibility of using the SGLT2 impediments in cases with HFmrEF [50] cannot be barred. piecemeal from SGLT2 impediments, which have given positive results, the exploration precedences must concentrate on chancing an effective remedial strategy for HFpEF, a primary unmet need in cardiovascular drug. This would bear great trouble and determination given the diversity of cases, underpinning comorbidities that drive this pattern. It would be pivotal, together with prostrating individual challenges, to interpret pathophysiological aspects of HFpEF that are currently unclear.

7 .WHAT IS IN THE FUTURE….. ?

7.1 Future Impact Of Mrna Therapy:

The table were filling of the recent epidemic was that it accelerated the emergence of runner ribonucleic acid (mRNA) rectifiers. The great pledge of mRNA rectifiers was stressed by the speed at which the vaccines were created, tested, and proven to be fairly safe and largely effective. There are a wide variety of mRNA rectifiers now under development, and dozens of these are in clinical trials. These rectifiers are generating a major paradigm shift in medical remedy, including the treatment of cardiovascular complaint. Utmost of the cardiovascular mRNA curatives are Still in preclinical development, although a phase 2a trial of mRNA remedy for myocardial ischemia has been completed with promising results. The operation of mRNA curatives to cardiovascular conditions is nearly measureless, and ongoing work includes mRNA curatives for myocardial ischemia, heart failure, arrhythmias, hypercholesterolemia, and arterial occlusive conditions. In addition, mRNA may be used to enhance cell curatives. In the future, mRNA curatives for cardiovascular complaint are fated to displant some of our current biologics and pharmacotherapy and will be used to treat preliminarily untreatable cardiovascular conditions. Likewise, mRNA curatives can be substantiated, and they can be fleetly generated in current Good Manufacturing Practice installations with a modest footmark, easing the rise of sanitarium-grounded indigenous centers of RNA rectifiers.[52]

7.2 Future Impact Of Gene Therapy:

The birth of gene remedy for cardiovascular diseases in the medial 1990s coincided with a series of attempts at converting remedial angiogenesis in cases with coronary or supplemental roadway complaint. These operations were fueled by the notion that new blood vessel conformation is a cytokine-driven process and that the over expression of some of the angiogenic cytokines was sufficient to break acute conditions of ischemia in beast models. Yet, after over 150 clinical trials, there isn't a single successful operation to achieve remedial angiogenesis in humans. New blood vessel conformation in adult life occurs through capillary sprouting from antedating vessels, a process that's touched off and maintained by buried factors first acting on endothelial cells and .latterly converting development of the recently formed capillaries[53] Over 20 clinical operations in the late 1990s and early 2000s have included the intramyocardial injection of plasmids garbling VEGF(vascular endothelial growth factor)- A[54], one of the master controller of the angiogenesis process(reviewed in study by Giacca and Zacchigna) [55]. Some positive results from these operations are largely anecdotal, as these had an open-labeled designed and the placebo effect is notoriously strong in angiogenic curatives. When randomized, double-blindfolded, placebo-controlled trials with naked plasmid DNA injection were performed, these failed to show a major
positive impact on either clinical outgrowth or symptoms (the
EUROINJECT1,[56] NORTHERN (NOGA Angiogenesis
Revascularization Therapy Assessment by Radio Nuclide Imaging) [57], and KAT (Kuopio Angiogenesis Trial) [58]. Wrong results were also reported for abi-cistronic plasmid garbling both FGF2 and VEGF- A [54], (the VIF- CAD study) [59], and in one small study aimed at adding VEGF- A [54] plasmid efficacy by the administration of G- CSF (granulocyte colony stimulating factor)[60], fresh clinical studies with intramyocardial plasmid delivery are ongoing for hepatocyte growth factor, grounded on a former, small clinical Phase I trial.[61]



7.3 Monoclonal Antibody For Heart Disease Therapy:

Cardiovascular diseases are the leading cause of death and the topmost healthcare cost worldwide. In Italy, over 20 billion euros a time are spent on treating these diseases. And the figures are set to grow over the coming times.

A new study published in Nature Dispatches has shown the efficacity of a new natural medicine, a monoclonal antibody able of blocking fibrosis and guarding the heart muscle after myocardial infarction. The study showed that this antibody has a salutary effect by means of a double medium on the one hand, it reduces the deposit of
stringy towel which limits the heart's pump function, and on the other,
it promotes the survival of heart muscle cells.

The study, led by Serena Zacchigna, professor of Molecular Biology at the University of Trieste and head of the Cardiovascular Biology lab of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, represents a turning point in the sector of innovative cardiovascular curatives.

“In discrepancy to the great social and healthcare pressure wielded by these conditions, the medicines we use to treat cases with heart complaint are rather dated. New natural curatives”-explains Zacchigna – “are transubstantiating oncological or heritable complaint treatments, while there are veritably many natural medicines for the treatment of cardiovascular diseases. The vast maturity of curatives approved to date are small chemical motes that generally have a single target, blocking the action of an enzyme or receptor, for illustration. By discrepancy, natural medicines (recombinant proteins, gene remedy products and cell remedy) reproduce rudiments that typically live in our apkins and thus, have the eventuality to intrude with complex remedy mechanisms. Still, they're more delicate to prepare and use, as well as being more precious, making them complicated to restate from experimental studies to cases". This study, which is the result of a long collaboration between the Trieste institutes (ICGEB and University of Trieste) and the University of Zagreb, Croatia, reveals the abecedarian part of a family of proteins, called Bone Morphogenetic Proteins(BMPs), in the elaboration of cardiac fibrosis after an ischemic event.

For times, the Croatian platoon has been a centre of excellence for the study of BMPs which, as the name implies, play a crucial part in bone conformation, but which have lately also been intertwined in other processes, similar as fibrosis. “Having been suitable to unite with our Croatian associates”- says Andrea Colliva, first author of the study and Units experimenter working at ICGEB – “ has allowed us to test the effectiveness of a monoclonal antibody which blocks a particular interpretation of BMP protein (BMP1.3), whose situations are particularly high in cases brought to the exigency room for a myocardial infarction".

In the last phase of the design, a group of cardiac surgeons from Innsbruck joined the Trieste-Zagreb axis and contributed their gets and chops to the mechanisms underpinning ischemic damage and the development of innovative curatives. This was made possible by the IN Cardio design-Innovative curatives for Cardiovascular diseases, led by ICGEB and financed by the European Regional Development Fund and by Interred V-A Italy – Austria 2041-2021.

Promoting cross-border invention in the treatment of cardiovascular diseases is precisely the main ideal of the IN cardio cross-border design, which has consolidated the design and unites about thirty experimenters working in the sector." We're confident that this work will open the door to other natural medicines in the cardiovascular sector” concludes Zacchigna, “as we need cooperation and collaboration among different chops to insure that the study results can reach cases and that this can also be applied in Italy"[62].

7.4 Drugs Stimulating The Non-Classic RAAS:

The mortal recombinant ACE2 and agonists of MAS1 receptors were pre-clinically estimated for cardiovascular conditions [63]. Specifically, the mortal recombinant ACE2

showed the capability to reduce AII- intermediated cardiac redoing and myocardial fibrosis in wild- type mice [64], and to have a defensive effect in murine models of AII- convinced HF [65]. also, the mortal recombinant ACE2 completed phase I (NCT00886353) and phase II (NCT01597635) clinical trials, showing a good safety profile with no apparent cardiovascular effect in healthy subjects [66]. Among MAS1 receptor agonists delevered for treating cardiovascular conditions are the nonpeptide emulsion Adieu 0991 and the A1 – 7. While Adieu 0991 was studied in an experimental model of hypertension, the A1 – 7 was delved in colour full murine models of HF with reduced or saved ejection bit showing salutary cardioprotective goods [65]. Still, despite the long- lasting preclinical exploration on A1 – 7 are ongoing for a long time, the real clinical restatement is still far down. While some registered clinical trials were terminated beforehand due to difficulties in the reclamation of subjects (ClinicalTrials.gov Identifier NCT03159988, NCT02591173), the question why innumerous cases of introductory exploration weren't applied in clinical reality remains to be addressed.

8. CONCLUSIONS

The RAAS exertion is increased in cases with heart failure, and when this medium turns maladaptive, targeting the factors of RAAS produces significant benefits. ACE impediments remain the first-line remedy for all cases with HFrEF , but a substantial gap exists for cases with HFpEF/ HFmrEF. Indeed, the new medicine class of ARNI was set up effective only in HFrEF cases. In this regard, stimulating the non-classic RAAS (ACE2 and A1 – 7) might be a new strategy for heart failure, including phenotypes with saved and mildly-reduced ejection bit. Therefore, further introductory, translational and clinical exploration is demanded to delineate the benefits of targeting non-classic RAAS. At the same time, the most promising strategy arising for HFpEF are the SGLT2 impediments that have lately been shown to reduce worsening heart failure and cardiovascular death in cases with HFrEF, reaching snappily the prominent position in HF guidelines. On the negative, although inflammation undisputedly contributes to the onset and progression of habitual heart failure, anti-inflammatory and immunomodulating strategies are yet to be restated into clinically effective approach. Eventually, miRNAs, gene and epigenetic curatives that carry the eventuality to modulate neurohormonal and vulnerable activation are still far from clinical arena.

9. REFERENCES

1. World Health Organization, Cardiovascular Diseases (CVDs), 2021. Published online 11 June. 〈 https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)〉. (Accessed 2 September 2021).

2. T.A. McDonagh, M. Metra, M. Adamo, R.S. Gardner, A. Baumbach, M. Böhm, H. Burri, J. Butler, J. Čelutkienė, O. Chioncel, J. Cleland, A. Coats, M.G. Crespo-Leiro, D. Farmakis, M. Gilard, S. Heymans, A.W. Hoes, T. Jaarsma, E.A. Jankowska, M. Lainscak, C. Lam, A.R. Lyon, J. McMurray, A. Mebazaa, R. Mindham, C. Muneretto, M. Francesco Piepoli, S. Price, G. Rosano, F. Ruschitzka, A. Kathrine Skibelund, G. ESC Scientific Document
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
Eur. Heart J., 42 (2021), pp. 27-3726, 10.1093/EURHEARTJ/EHAB368

3. V.L. Roger
Epidemiology of heart failure
Circ. Res., 113 (6) (2013), pp. 646-659, 10.1161/CIRCRESAHA.113.300268

4. G. Karayannis, G. Kitsios, H. Kotidis, F. Triposkiadis

Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure
Heart Fail. Rev., 13 (2008), pp. 91-98

5. G. Karayannis, G. Kitsios, H. Kotidis, F. Triposkiadis Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure Heart Fail. Rev., 13 (2008), pp. 91-98

6. M.R. Bristow
β-Adrenergic receptor blockade in chronic heart failure
Circulation, 101 (2000), pp. 558-569

8. F. Rossi, A. Mascolo, V. Mollace
The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure
Int. J. Cardiol., 226 (2017), pp. 121-125

9. J.W. Funder
Reconsidering the roles of the mineralocorticoid receptor
Hypertension, 53 (2009), pp. 286-290

10. U. Steckelings, L. Paulis, P. Namsolleck, T. Unger
AT2 receptor agonists: hypertension and beyond
Curr. Opin. Nephrol. Hypertens., 21 (2012), pp. 142-146

11. A. Mascolo, M. Sessa, C. Scavone, A. De Angelis, C. Vitale, L. Berrino, F. Rossi, G. Rosano, A. Capuano
New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): Focus on cardiovascular and neurological diseases
Int. J. Cardiol., 227 (2017), pp. 734-742, 10.1016/j.ijcard.2016.10.069

12. E.N. Chauvel, P. Coric, C. Llorens-Cortés, S. Wilk, B.P. Roques, M.C. Fournié-Zaluski
Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors
J. Med. Chem., 37 (1994), pp. 1339-1346

13. F.H.H. Leenen, M. Ahmad, Y. Marc, C. Llorens-Cortes
Specific inhibition of brain angiotensin III formation as a new strategy for prevention of heart failure after myocardial infarction
J. Cardiovasc. Pharmacol., 73 (2019), pp. 82-91

14. F.H.H. Leenen, M. Ahmad, Y. Marc, C. Llorens-Cortes
Specific inhibition of brain angiotensin III formation as a new strategy for prevention of heart failure after myocardial infarction J. Cardiovasc. Pharmacol., 73 (2019), pp. 82-91

15. L. Ren, X. Lu, A.H.J. Danser Revisiting the Brain Renin-Angiotensin System-Focus on Novel Therapies
Curr. Hypertens. Rep., 21 (2019), p. 28, 10.1007/s11906-019-0937-8

16. Y. Goto, A. Hattori, Y. Ishii, S. Mizutani, M. Tsujimoto Enzymatic properties of human aminopeptidase A. Regulation of its enzymatic activity by calcium and angiotensin IV
J. Biol. Chem., 281 (2006), pp. 23503-23513

17. R. Santos, A. Ferreira, T. Verano-Braga, M. Bader
Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system R1-R17
J. Endocrinol., 216 (2013), 10.1530/JOE-12-0341

PMID: 23092879

18. A. Mascolo, C. Scavone, C. Rafaniello, C. Ferrajolo, G. Racagni, L. Berrino, G. Paolisso, F. Rossi, A. Capuano
Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review
Front. Cardiovasc. Med., 7 (2020), p. 143,

19. A. Lymperopoulos, G. Rengo, W. Koch
Adrenergic nervous system in heart failure: pathophysiology and therapy
Circ. Res., 113 (2013), pp. 739-753

20. F.H.H. Leenen
Brain mechanisms contributing to sympathetic hyperactivity and heart failure
Circ. Res., 101 (2007), pp. 221-223

21. S. Sridharan, R.M. Kini, A.M. Richards
Venom natriuretic peptides guide the design of heart failure therapeutics
Pharmacol. Res., 155 (2020), Article 104687

22. A.M. Richards
The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides
Heart, 76 (1996), pp. 36-44

23. T. Maack, M. Suzuki, F.A. Almeida, D. Nussenzveig, R.M. Scarborough, G.A. McEnroe, J.A. Lewicki
Physiological role of silent receptors of atrial natriuretic factor
Science, 238 (1987), pp. 675-678

24. A.M. Richards, G. Tonolo, M. Tree, J.I. Robertson, P. Montorsi, B.J. Leckie, J. Polonia
Atrial natriuretic peptides and renin release
Am. J. Med., 84 (1988), pp. 112-118

25. Pharmacology education Glycosides Available:http://www.pharmacologyeducation.org/positive-inotropic-drugs-cardiac-glycosides-digoxin (accessed 3.6.2021)

26. C.A. Romero, M. Orias, M.R. Weir
Novel RAAS agonists and antagonists: clinical applications and controversies
Nat. Rev. Endocrinol., 11 (2015), pp. 242-252

27. G. Filippatos, S.D. Anker, M. Böhm, M. Gheorghiade, L. Køber, H. Krum, A.P. Maggioni, P. Ponikowski, A.A. Voors, F. Zannad, S.Y. Kim, C. Nowack, G. Palombo, P. Kolkhof, N. Kimmeskamp-Kirschbaum, A. Pieper, B. Pitt
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Eur. Heart J., 37 (2016)

28. O. Vardeny, B. Claggett, J. Kachadourian, A.S. Desai, M. Packer, J. Rouleau, M.R. Zile, K. Swedberg, M. Lefkowitz, V. Shi, J. McMurray, S.D. Solomon
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial
Eur. J. Heart Fail., 21 (2019), pp. 337-341

29. G. Sinagra, U. Corrà, M. Contini, D. Magrì, S. Paolillo, P. Perrone Filardi, S. Sciomer, R. Badagliacca, P. Agostoni

Choosing among β-blockers in heart failure patients according to β-receptors' location and functions in the cardiopulmonary system
Pharmacol. Res., 156 (2020), Article 104785

30. V. Mollace, M. Gliozzi, A. Capuano, F. Rossi
Modulation of RAAS-natriuretic peptides in the treatment of HF: Old guys and newcomers
Int. J. Cardiol., 226 (2017), pp. 126-131

31. J.J. McMurray, M. Packer, A.S. Desai, J. Gong, M.P. Lefkowitz, A.R. Rizkala, J.L. Rouleau, V.C. Shi, S.D. Solomon, K. Swedberg, M.R. Zile, C. PARADIGM-HF Investigators
Angiotensin-neprilysin inhibition versus enalapril in heart failure
N. Engl. J. Med., 371 (2014), pp. 993-1004, 10.1056/NEJMoa1409077

32. J.P. Seferovic, B. Claggett, S.B. Seidelmann, E.W. Seely, M. Packer, M.R. Zile, J.L. Rouleau, K. Swedberg, M. Lefkowitz, V.C. Shi, A.S. Desai, J. McMurray, S.D. Solomon
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Lancet Diabetes Endocrinol., 5 (2017), pp. 333-340

33. K. Damman, M. Gori, B. Claggett, P.S. Jhund, M. Senni, M.P. Lefkowitz, M.F. Prescott, V.C. Shi, J.L. Rouleau, K. Swedberg, M.R. Zile, M. Packer, A.S. Desai, S.D. Solomon, J. McMurray
Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure
JACC Heart Fail., 6 (2018), pp. 489-498

34. A.S. Desai, O. Vardeny, B. Claggett, J.J. McMurray, M. Packer, K. Swedberg, J.L. Rouleau, M.R. Zile, M. Lefkowitz, V. Shi, S.D. Solomon
Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial
JAMA Cardiol., 2 (2017), pp. 79-85

35. M. Packer, S.D. Anker, J. Butler, et al.
Cardiovascular and renal outcomes with empagliflozin in heart failure
N. Engl. J. Med., 383 (2020), pp. 1413-1424, 10.1056/NEJMoa2022190

36. J.J.V. McMurray, S.D. Solomon, S.E. Inzucchi, et al.
Dapagliflozin in patients with heart failure and reduced ejection fraction
N. Engl. J. Med., 381 (2019), pp. 1995-2008, 10.1056/NEJMoa1911303

37. F. Zannad, J.P. Ferreira, S.J. Pocock, S.D. Anker, J. Butler, G. Filippatos, M. Brueckmann, A.P. Ofstad, E. Pfarr, W. Jamal, M. Packer
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

38. C.N. Koyani, I. Plastira, H. Sourij, S. Hallström, A. Schmidt, P.P. Rainer, H. Bugger, S. Frank, E. Malle, D. von Lewinski
Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
Pharmacol. Res., 158 (2020), Article 104870

39. J. Wintrich, I. Kindermann, C. Ukena, et al.
Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
Clin. Res. Cardiol., 109 (2020), pp. 1079-1098
40. J. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, J. Taylor
The perindopril in elderly people with chronic heart failure (PEP-CHF) study
Eur. Heart J., 27 (2006), pp. 2338-2345
41. B.M. Massie, P.E. Carson, J.J. McMurray, M. Komajda, R. McKelvie, M.R. Zile, S. Anderson, M. Donovan, E. Iverson, C. Staiger, A. Ptaszynska, I. I-PRESERVE

Irbesartan in patients with heart failure and preserved ejection fraction
N. Engl. J. Med., 359 (2008), pp. 2456-2467

42. B. Pitt, M.A. Pfeffer, S.F. Assmann, et al.
Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function
N. Engl. J. Med., 258 (2014), p. 10, 10.1056/NEJMoa1313731

43. A. Ahmed, M.W. Rich, J.L. Fleg, M.R. Zile, J.B. Young, D.W. Kitzman, T.E. Love, W.S. Aronow, Jr Adams KF, M. Gheorghiade
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial
Circulation, 114 (2006), pp. 397-403

44. S.D. Solomon, J.J.V. McMurray, I.S. Anand, J. Ge, C. Lam, A.P. Maggioni, F. Martinez, M. Packer, M.A. Pfeffer, B. Pieske, M.M. Redfield, J.L. Rouleau, D.J. van Veldhuisen, F. Zannad, M.R. Zile, A.S. Desai, B. Claggett, P.S. Jhund, S.A. Boytsov, J. Comin-Colet, J. Cleland, H.D. Düngen, E. Goncalvesova, T. Katova, J.F. Kerr Saraiva, M. Lelonek, B. Merkely, M. Senni, S.J. Shah, J. Zhou, A.R. Rizkala, J. Gong, V.C. Shi, M.P. Lefkowitz, C. PARAGON-HF Investigators
Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction, angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction
N. Engl. J. Med., 381 (2019), pp. 1609-1620, 10.1056/NEJMoa1908655

45. A.A. Bavry, Angiotensin Receptor Neprilysin Inhibition Compared With Individualized Medical Therapy for Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction, American College of Cardiology, 2020. Published online 30 August.
https://www.acc.org/latest-in-cardiology/clinical-trials/2020/08/28/17/06/paralla〉

46. A. Capuano, C. Scavone, C. Vitale, L. Sportiello, F. Rossi, G.M. Rosano, A.J. Coats
Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF)
Int. J. Cardiol., 200 (2015), pp. 15-19

47. S.D. Anker, J. Butler, G. Filippatos, et al., Empagliflozin in Heart Failure with a Preserved Ejection Fraction, 2021. Published online 27 August.

48. European Society of Cardiology, Trial Reports First Successful Results for Heart Failure with Preserved Ejection Fraction, 2021. Published online 27 August https://www.escardio.org/The-ESC/Press-Office/Press-releases/Trial-reports-first-successful-results-for-heart-failure-with-preserved-ejection-fraction

49. European Society of Cardiology, Empagliflozin Benefits Heart Failure Patients with Reduced and Preserved Ejection Fraction, 2021. Published online 27 August. 〈https://www.escardio.org/The-ESC/Press-Office/Press-releases/Empagliflozin-benefits-heart-failure-patients-with-reduced-and-preserved-ejection-fraction〉

50. S. Anker, M. Khan, I. Shahid, G. Filippatos, A. Coats, J. Butler
Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism
Eur. J. Heart Fail., 23 (2021), pp. 1250-1255

51. L. Uthman, A. Homayr, R.P. Juni, E.L. Spin, R. Kerindongo, M. Boomsma, M.W. Hollmann, B. Preckel, P. Koolwijk, V. van Hinsbergh, C.J. Zuurbier, M. Albrecht, N.C. Weber
Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells

52. Collén A, Bergenhem N, Carlsson L, et al. VEGFA mRNA for regenerative treatment of heart failure. Nat Rev Drug Discov. 2022. Jan;21(1):79-80. doi: 10.1038/s41573-021-00355-6

53. Risau W. Mechanisms of angiogenesis.Nature. 1997; 386:671–674. doi: 10.1038/386671a0

54. Gabisonia K, Prosdocimo G, Aquaro GD, Carlucci L, Zentilin L, Secco I, Ali H, Braga L, Gorgodze N, Bernini F, et al. MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs.Nature. 2019; 569:418–422. doi: 10.1038/s41586-019-1191-6

55. Giacca M, Zacchigna S. VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond.Gene Ther. 2012; 19:622–629. doi: 10.1038/gt.2012.17

56. Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W, Bøtker HE, Dudek D, Drvota V, Hesse B, et al; Euroinject One Group. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial.J Am Coll Cardiol. 2005; 45:982–988. doi: 10.1016/j.jacc.2004.12.

57. Stewart DJ, Kutryk MJ, Fitchett D, Freeman M, Camack N, Su Y, Della Siega A, Bilodeau L, Burton JR, Proulx G, et al; NORTHERN Trial Investigators. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial.Mol Ther. 2009; 17:1109–1115. doi: 10.1038/mt.2009.70

58. Hedman M, Hartikainen J, Syvänne M, Stjernvall J, Hedman A, Kivelä A, Vanninen E, Mussalo H, Kauppila E, Simula S, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).Circulation. 2003; 107:2677–2683. doi: 10.1161/01.CIR.0000070540.80780.92

59. Kukuła K, Chojnowska L, Dąbrowski M, Witkowski A, Chmielak Z, Skwarek M, Kądziela J, Teresińska A, Małecki M, Janik P, et al. Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD).Am Heart J. 2011; 161:581–589. doi: 10.1016/j.ahj.2010.11.023

60. Ripa RS, Wang Y, Jørgensen E, Johnsen HE, Hesse B, Kastrup J. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease.Eur Heart J. 2006; 27:1785–1792. doi: 10.1093/eurheartj/ehl117

61. Wang LS, Wang H, Zhang QL, Yang ZJ, Kong FX, Wu CT. Hepatocyte growth factor gene therapy for ischemic diseases.Hum Gene Ther. 2018; 29:413–423. doi: 10.1089/hum.2017.217

62. Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction
http://www.nature.com/ncomms

63. A. Mascolo, C. Scavone, C. Rafaniello, A. De Angelis, K. Urbanek, G. di Mauro, D. Cappetta, L. Berrino, F. Rossi, A. Capuano
The role of renin-angiotensin-aldosterone system in the heart and lung: focus on COVID-19
Front. Pharmacol., 12 (2021), p. 12,

64. J. Zhong, R. Basu, D. Guo, F.L. Chow, S. Byrns, M. Schuster, H. Loibner, X. Wang, J.M. Penninger, Z. Kassiri, G.Y. Oudit
Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction
Circulation, 122 (2010), pp. 717-728

65. V. Patel, J. Lezutekong, X. Chen, G. Oudit

Recombinant human ACE2 and the angiotensin 1-7 axis as potential new therapies for heart failure
Can. J. Cardiol., 33 (2017), pp. 943-946

66. M. Haschke, M. Schuster, M. Poglitsch, H. Loibner, M. Salzberg, M. Bruggisser, J. Penninger, S. Krähenbühl
Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects
Clin. Pharmacokinet., 52 (2013), pp. 783-792